WASHINGTON (Reuters) - There is no evidence that brand-name drugs given to treat heart and other cardiovascular conditions work any better than their cheaper generic counterparts, U.S. researchers said on Tuesday.
The findings run counter to the perception by some doctors and patients that pricier brand-name drugs are clinically superior, said Dr. Aaron Kesselheim of Brigham and Women's Hospital and Harvard Medical School in Boston, who led the study.
Kesselheim and colleagues combined the results of 30 studies done since 1984 comparing nine sub-classes of cardiovascular drugs to generic counterparts.
The brand-name drugs did not offer any advantage for patients' clinical outcomes in those studies, they wrote in the Journal of the American Medical Association.
"Brand-name drugs for cardiovascular disease can be as much as a few dollars a pill, whereas generic drugs might be as little as a few cents a pill," Kesselheim said.
"If a patient is prescribed a generic drug because that's what's appropriate for their condition, then they should feel confident taking that drug. And physicians themselves should also feel confident prescribing generic drugs where appropriate," Kesselheim said in a telephone interview.
He said rising costs of brand-name prescription drugs strain the budgets of patients as well as public and private health insurers. Overall U.S. prescription drug sales hit $286.5 billion in 2007.
© 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
http://GizmoHealth.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment